Shares of Stryker climbed 3.2% following Raymond James analyst Jayson Bedford’s upgrade to “outperform,” with a 12-month price target of $418. Bedford highlighted Stryker’s fifth consecutive year of organic revenue growth exceeding 10%, noting consistent market share gains across its MedSurg, Neurotechnology and Orthopaedics divisions. He argued that a recent contraction of the forward P/E multiple by roughly three turns—from about 26x to 23x—unduly penalizes the company’s double-digit growth profile and potential upside to consensus estimates. However, some investors question whether the stock’s current valuation—near 46x trailing GAAP earnings—justifies only 10% growth, and suggest the multiple may need to compress before delivering attractive returns.

Stryker has scheduled its fourth quarter and full year 2025 financial results release for January 29, 2026, with a press release at approximately 4:05 p.m. ET and a live webcast at 4:30 p.m. ET. The company will provide summary financial information for the period ending December 31, 2025, and an archived replay will be available two hours after the call. In conjunction with the announcement, Stryker declared a quarterly dividend of $0.88 per share, payable January 30, 2026, and appointed Spencer Stiles as President and Chief Operating Officer, strengthening its leadership team ahead of the new fiscal year.